# Vanda Pharmaceuticals shares were trading above previous 52-week highs in the after-hours market.

*biotech · news · 2025-12-31 · MarketScreener*

## Key points

- The FDA approved Vanda Pharmaceuticals' Nereus for preventing motion-induced vomiting.
- Nereus is the first newly approved drug for motion sickness in over four decades.
- Vanda shares rose nearly 13% in after-hours trading after the FDA approval announcement.
- The stock surpassed its previous 52-week high, reaching $7.93 post-approval.

By Stephen Nakrosis Shares of Vanda Pharmaceuticals were trading above previous 52-week highs in the after-hours market, following news that the U.S. Food and Drug Administration approved Nereus as a treatment to prevent vomiting induced by motion. After the bell, the company's shares were trading nearly 13% higher, at $7.93. The stock previously hit a 52-week high of $7.46 on Dec. 29. The company's shares finished the day's regular session with a 2.3% loss, closing at $7.03. Year to date, the stock is up over 46%. Vanda said the approval is the first for a new pharmacologic treatment in motion sickness in over four decades. Write to Stephen Nakrosis at stephen.nakrosis@wsj.com (END) Dow Jones Newswires 12-30-25 1901ET

**Countries:** United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/vanda-pharma-shares-rise-after-fda-approves-motion-sickness-treatment-ce7e59d8dd8afe25)

---

Canonical: https://newsio.io/n/acd5b3f0-0f9d-432e-8457-2c4f85185553/vanda-pharmaceuticals-shares-were-trading-above-previous-52-week-highs-in-the-af
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works